News

According to Frost & Sullivan analysis most pharmaceutical companies consider emerging markets lucrative due to their economical infrastructure and manpower costs and a significant untapped market potential with

The patent, when issued, will provide Japanese patent protection to September 2021 and is one in a series of patents and pending applications that NexMed owns on Vitaros

Cellceutix said that its team has identified an animal model and has been successful in chemically inducing these characteristics in the model. KM-391 has shown to be successful

Neogenix said that the USPT0 has issued a patent for the NPC-1C monoclonal antibody and a related divisional patent was granted with respect to the genes encoding the

The second license agreement provides GSK with access to BioWa’s Complegent Technology for enhancing the complement-dependent cytotoxicity (CDC) of select GSK therapeutic antibodies. These two technologies may be

Probactive Biotech said that it has combined medical-grade Iodine-131 and Yttrium-90 with antitumor antibodies, producing targeted anticancer activity. The parts of the research and development program is expected

The new facility is expected to allow OvaGene Oncology to perform genomic testing on cancer cells using advanced technologies such as Quantitative Polymerase Chain Reaction (QPCR), Comparative Genomic

Lucentis is a vascular endothelial growth factor (VEGF) inhibitor which was first approved by the FDA for the treatment of neovascular (wet) age-related macular degeneration (AMD) in 2006.

Scil Proteins’ product, SPVF 2801, an Affilin molecule for applications in solid tumors passed initial preclinical studies with good results. Affilin molecules are scaffold proteins derived from the